Corcept Therapeutics Incorporated (NASDAQ: CORT) Q1 2023 Earnings Call dated May. 03, 2023 Corporate participants: Atabak Mokari -- Chief Financial Officer Charlie
Corcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Call Transcript
Categories
Health Care
Sage Therapeutics Inc (SAGE) Q1 2023 Earnings Call Transcript
Sage Therapeutics Inc (NASDAQ:SAGE) Q1 2023 Earnings Call dated May. 02, 2023. Corporate Participants: Helen Rubinstein -- Director of Investor Relations Barry Greene -- Chief Executive
10X Genomics Inc (TXG) Q1 2023 Earnings Call Transcript
10X Genomics Inc (NASDAQ: TXG) Q1 2023 Earnings Call dated May. 03, 2023 Corporate participants: Cassie Corneau -- Head, Investor Relations &
CVS Health Corporation (CVS) Q1 2023 Earnings Call Transcript
CVS Health Corporation (NYSE: CVS) Q1 2023 Earnings Call dated May. 03, 2023 Corporate participants: Larry McGrath -- Senior Vice-President of Business
Pfizer (PFE): Declines in COVID-19 products expected to drag down overall revenue in 2023
Shares of Pfizer Inc. (NYSE: PFE) were down on Tuesday despite the company delivering better-than-expected results for the first quarter of 2023.
A snapshot of AmerisourceBergen’s Q2 2023 earnings results
Pharmaceutical solutions provider AmerisourceBergen Corporation (NYSE: ABC) reported higher revenues and adjusted earnings for the second quarter of 2023. Second-quarter revenue increased
PFE Earnings: All you need to know about Pfizer’s Q1 2023 earnings results
Pfizer Inc. (NYSE: PFE) reported first quarter 2023 earnings results today. Revenues declined 29% year-over-year to $18.3 billion. Reported net income fell
A snapshot of Stryker’s (SYX) Q1 2023 financial performance
Medical technology company Stryker Corporation (NYSE: SYK) announced operating results for the first quarter of 2023, reporting higher sales and profit. First-quarter
VRTX Earnings: A snapshot of Vertex Pharmaceuticals’ Q1 2023 results
Healthcare firm Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported a decline in adjusted earnings for the first quarter, despite an increase in
Trxade Health Inc. (NASDAQ: MEDS) Q1 2023 Research Summary
Trxade Health Inc. (NASDAQ: MEDS) is a healthcare IT company that operates as an integrated drug procurement and delivery platform. It is
ImmunoGen Inc (IMGN) Q1 2023 Earnings Call Transcript
ImmunoGen Inc (NASDAQ:IMGN) Q1 2023 Earnings Call dated Apr. 28, 2023. Corporate Participants: Anabel Chan -- Head, Investor Relations Mark Enyedy -- President & Chief Executive
IQVIA Holdings Inc (IQV) Q1 2023 Earnings Call Transcript
IQVIA Holdings Inc (NYSE: IQV) Q1 2023 Earnings Conference Call dated Apr. 27, 2023 Corporate Participants: Nick Childs -- Senior Vice President,
AMGN Earnings: Everything you need to know about Amgen’s Q1 results
Amgen Inc. (NASDAQ: AMGN) has reported lower revenues and adjusted earnings for the first quarter of 2023. The biotechnology firm also provided
Gilead Sciences (GILD) Earnings: 1Q23 Key Numbers
Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.4 billion for the first quarter of 2023, which was down 4% year-over-year.
Eli Lilly and Company (LLY) Q1 2023 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q1 2023 earnings call dated Apr. 27, 2023 Corporate Participants: Joe Fletcher -- Senior Vice President of Investor
Bristol-Myers Squibb (BMY) reports higher Q1 profit; revenue down 3%
Biotechnology company Bristol Myers Squibb (NYSE: BMY) said its first-quarter adjusted earnings increased modestly, despite a decline in revenues. Net income attributable
MRK Earnings: Highlights of Merck’s Q1 2023 financial results
Pharma firm Merck & Co., Inc. (NYSE: MRK) on Thursday reported lower earnings for the first quarter of 2023, due to a sharp
Earnings: Highlights of Eli Lilly & Company’s (LLY) Q1 2023 results
Eli Lilly and Company (NYSE: LLY) on Thursday reported lower earnings and revenues for the first quarter of 2023. The company also
Amgen Inc. (AMGN) Q1 2023 Earnings Call Transcript
Amgen Inc. (NASDAQ: AMGN) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Arvind Sood — Vice President, Investor Relations Robert A. Bradway — Chairman
Ocean Biomedical reports new results validating tumor suppression with anti-Chi3L1 antibody: EF Hutton raises OCEA price target to $17
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said its scientific co-founder Jack Elias published new findings in Cancer Research, a peer-reviewed
Merck & Co., Inc. (MRK) Q1 2023 Earnings Call Transcript
Merck & Co., Inc. (NYSE: MRK) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Peter Dannenbaum -- Vice President, Investor Relations Robert